Luye Pharma Group (HKG:2186) completed a U.S. bridging clinical trial for its investigational neurological drug LY03015, with results supporting the start of a U.S. efficacy trial.
The study found comparable pharmacokinetics between Chinese and Caucasian participants, while the drug showed a more favorable safety and tolerability profile in Caucasian subjects, according to a Wednesday Hong Kong bourse filing. No serious adverse events were reported.
LY03015 is being developed to treat tardive dyskinesia and Huntington's disease-related chorea.
Shares of the company rose marginally in recent trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments